Follow The Filings

COR Cencora

Health Care, filed as CENCORA INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.0%
  • $32K

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

  1. Kentucky Trust Co. 0.02%

Who owns COR

Sorted by value, long equity only, as of 2026 Q3.

History
Kentucky Trust Co., Kentucky Trust 0.02% Hold 105 $32K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by COR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All COR insider trades
  • $2.3M bought by 2 insiders
  • $7.2M sold by 4 insiders outside a trading plan
  • $7.9M sold by 2 insiders under 10b5-1 plans
  1. Lazarus Krikorian SVP & Chief Accounting Officer
    Planned sale
    $299K 986 shares at $303.18 6.1% of stake
    Traded Oct 1 Filed Oct 5
    ↗
  2. Lon R Greenberg Director
    Sale
    $411K 1,280 shares at $321.30 7% of stake
    Traded Sep 16 Filed Sep 17
    ↗
  3. Lazarus Krikorian SVP & Chief Accounting Officer
    Planned sale
    $321K 985 shares at $325.97 5.7% of stake
    Traded Sep 1 Filed Sep 2
    ↗
  4. Elizabeth S Campbell Executive Vice President
    Sale
    $3.7M 11,300 shares at $324.12 37% of stake
    Traded Aug 24 Filed Aug 25
    ↗
  5. Lauren M Tyler Director
    Buy
    $149K 550 shares at $270.23 +14% to stake
    Traded Jun 22 Filed Jun 24
    ↗
  6. Dermot Mark Durcan Director
    Buy
    $1.1M 4,000 shares at $274.19 +14% to stake
    Traded Jun 18 Filed Jun 22
    ↗
  7. Dermot Mark Durcan Director
    Buy
    $1.1M 4,000 shares at $266.26 +17% to stake
    Traded May 28 Filed May 28
    ↗
  8. Robert P. Mauch CEO
    Planned sale
    $1.4M 3,762 shares at $358.94 5.4% of stake
    Traded Feb 20 Filed Feb 24
    ↗
  9. Robert P. Mauch CEO
    Planned sale
    $479K 1,333 shares at $359.46 2% of stake
    Traded Feb 18 Filed Feb 20
    ↗
  10. Robert P. Mauch CEO
    Planned sale
    $1.8M 5,096 shares at $354.73 7.1% of stake
    Traded Jan 20 Filed Jan 22
    ↗
  11. Elizabeth S Campbell Executive Vice President
    Sale
    $1.1M 3,351 shares at $342.10 12% of stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
  12. Silvana Battaglia Executive Vice President
    Sale
    $579K 1,677 shares at $345.00 8.2% of stake
    Traded Dec 19, 2025 Filed Dec 22, 2025
    ↗
  13. Robert P. Mauch CEO
    Planned sale
    $1.8M 5,096 shares at $343.45 7% of stake
    Traded Dec 18, 2025 Filed Dec 22, 2025
    ↗
  14. Lazarus Krikorian SVP & Chief Accounting Officer
    Sale
    $1.4M 4,031 shares at $343.24 19% of stake
    Traded Dec 17, 2025 Filed Dec 19, 2025
    ↗
  15. Robert P. Mauch CEO
    Planned sale
    $1.9M 5,096 shares at $366.64 7.2% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 stock grants, 28 share withholdings for taxes, 27 option exercises, and 2 gifts.

Congress

4 members of Congress traded COR in the last three years: 5 buys and 4 sales. 8 members listed it in 2025 annual reports.

All Congress trades
  1. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  2. Jared Moskowitz D-FL-23 Sell $1K–$15K May 6 filed Jun 19
  3. Jared Moskowitz D-FL-23Child Sell $1K–$15K May 6 filed Jun 19
  4. Jared Moskowitz D-FL-23 Buy $1K–$15K Mar 31 filed Apr 30
  5. Jared Moskowitz D-FL-23 Buy $1K–$15K Mar 23 filed Apr 30
  6. Jared Moskowitz D-FL-23Child Buy $1K–$15K Mar 23 filed Apr 30

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 11 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $262.17B $293.96B $321.33B
Gross profit $8.96B $9.91B $11.48B
Gross margin * 3.4% 3.4% 3.6%
Net income $1.75B $1.51B $1.55B
Net margin * 0.7% 0.5% 0.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $42.8B $47.72B $52.24B
Total non-current assets * $19.76B $19.38B $24.35B
Total assets $62.56B $67.1B $76.59B
Total current liabilities $48.83B $54.28B $57.82B
Total equity $0.522B $0.646B $1.51B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $3.91B $3.48B $3.88B
Cash from investing -$2.6B -$0.618B -$4.98B
Cash from financing -$2.22B -$2.33B $2.25B
Net change in cash -$0.841B $0.545B $1.1B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.